Announcement: Eli Lilly’s Gene Editor Cuts Cholesterol 62% in First Human Trial

ბოლო განახლება: 26/06/2026 08:26

ავტორი:

0 Min Read

Eli Lilly's experimental gene-editing therapy VERV-102 achieved a 62% reduction in cholesterol levels at the highest dose in Phase 1 clinical trials. The single-dose treatment targets the PCSK9 gene to potentially provide permanent cholesterol control. — Photo by Supplements On Demand on Pexels (Pexels License)

1 min read|33 words

🧬 BREAKTHROUGH: Eli Lilly's gene-editing therapy cuts cholesterol by 62% with a single dose! VERV-102 targets the PCSK9 gene for potentially permanent treatment. Could revolutionize cardiovascular care.

Read the full article on GMJ Newsroom →

Was this article helpful?

GMJ Brief · Announcement

📰 Read the full article: Eli Lilly’s Gene Editor Cuts Cholesterol 62% in First Human Trial →

Share This Article

ავტორი:Prof. Giorgi Pkhakadze

Follow:

Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Announcement: Eli Lilly’s Gene Editor Cuts Cholesterol 62% in First Human Trial

Submit Your Paper →

Adding pirtobrutinib to venetoclax-rituximab improves survival in relapsed chronic lymphocytic leukemia

Long-term antihypertensive therapy shows diminishing cardiovascular benefits, meta-analysis of 51 trials reveals

BCG Vaccine Shows Promise in Reshaping Brain Immunity Against Alzheimer’s Disease

Submit Your Paper to GMJ

Company

You Might Also Like